You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapse Multiple Sclerosis (RMS)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial (Dimethyl fumarate)

Not yet recruiting
  • Multiple Sclerosis
  • Dimethyl fumarate
  • (no location specified)
Dec 12, 2022

Early Versus Late Ofatumumab Use in Austrian RMS-Patients Over 2

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 17, 2023

Relapsing Multiple Sclerosis (RMS) Trial in China (Fingolimod 0.5mg)

Recruiting
  • Relapsing Multiple Sclerosis (RMS)
  • Fingolimod 0.5mg
  • Beijing, Beijing, China
  • +12 more
Feb 3, 2022

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Phoenix, Arizona
  • +12 more
Nov 11, 2021

Multiple Sclerosis Trial in Cairo (Blood sample collection)

Recruiting
  • Multiple Sclerosis
  • Blood sample collection
  • Cairo, Egypt
    Nasser Institute for Research and Treatment
Feb 21, 2023

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Carlsbad, California
  • +13 more
Nov 5, 2021

Elevated Factor VIII Related Labs asBiomarker for Incomplete

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • blood tests drawn days 1, 8, 22 and 90 of the study
  • (no location specified)
Jun 22, 2023

Relapsing Forms of Multiple Sclerosis Trial in Australia, United States (EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD)

Recruiting
  • Relapsing Forms of Multiple Sclerosis
  • EHP-101 25 mg OD
  • +3 more
  • Cullman, Alabama
  • +3 more
Apr 29, 2022

Deficient T Regulatory Cell Function in Relapsing Remitting

Recruiting
  • Relapse Remitting Multiple Sclerosis
    • Philadelphia, Pennsylvania
      Thomas Jefferson University
    Jun 13, 2022

    RMS Patients on Ofatumumab or Ocrelizumab inReal-World Setting

    Recruiting
    • Relapsing Multiple Sclerosis
    • Ofatumumab
    • Ocrelizumab
    • Dubai, United Arab Emirates
      Novartis Investigative Site
    Aug 8, 2022

    Suboptimally Controlled Participants Previously Taking Oral or

    Recruiting
    • Multiple Sclerosis
    • Cladribine Tablets
    • Cullman, Alabama
    • +66 more
    Nov 29, 2022

    Multiple Sclerosis Trial in Germany (Ofatumumab)

    Active, not recruiting
    • Multiple Sclerosis
    • Berlin, Germany
    • +5 more
    Jan 13, 2023

    Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)

    Active, not recruiting
    • Relapsing Remitting Multiple Sclerosis
    • Ublituximab
    • Pasadena, California
    • +7 more
    Aug 19, 2022

    Multiple Sclerosis Trial in Los Angeles (Blood draw for future biomarker analysis)

    Completed
    Has Results
    • Multiple Sclerosis
    • Blood draw for future biomarker analysis
    • Los Angeles, California
      Investigational Site Number 8400001
    Mar 15, 2022

    Suboptimally Controlled Participants Previously Taking

    Active, not recruiting
    • Multiple Sclerosis
    • Cladribine Tablets
    • Cullman, Alabama
    • +38 more
    Jul 19, 2022

    Relapsing Multiple Sclerosis Trial in Worldwide (fenebrutinib, )

    Recruiting
    • Relapsing Multiple Sclerosis
    • Fullerton, California
    • +16 more
    Jan 24, 2023

    Multiple Sclerosis Trial in Izmir (Video game-based physical activity training, Conventional physiotherapy program)

    Completed
    • Multiple Sclerosis
    • Video game-based physical activity training
    • Conventional physiotherapy program
    • Izmir, Turkey
      Dokuz Eylul University Hospital, Neurology Department
    May 30, 2022

    Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis Relapse Trial in Istanbul (in-vivo Corneal Confocal Microscopy)

    Completed
    • Multiple Sclerosis, Relapsing-Remitting
    • Multiple Sclerosis Relapse
    • in-vivo Corneal Confocal Microscopy
    • Istanbul, Turkey
      Marmara University
    Jan 20, 2022

    Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive Trial in San Francisco

    Not yet recruiting
    • Multiple Sclerosis (MS)
    • +6 more
    • Clemastine Fumarate
    • Placebo
    • San Francisco, California
      Sandler Neurosciences Building, Neurological Clinical Research U
    Jan 23, 2023

    Multiple Sclerosis, Relapsing-Remitting Trial in Hamburg (web-based intervention programme, web-based information material

    Active, not recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • web-based intervention programme
    • web-based information material offered via the same platform (broca®) in addition to usual care
    • Hamburg, Germany
      Universitätsklinikum Hamburg-Eppendorf
    Jun 21, 2022

    Offspring Neurocognitive Development and Behaviour

    Recruiting
    • Multiple Sclerosis
    • Exposure to methylprednisolone during pregnancy
    • Bochum, Germany
    • +1 more
    Aug 8, 2022

    Progressive Multiple Sclerosis Trial in Lille, Strasbourg (Placebo, Masitinib (4.5))

    Recruiting
    • Progressive Multiple Sclerosis
    • Placebo
    • Masitinib (4.5)
    • Lille, France
    • +1 more
    Jul 1, 2022

    Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

    Terminated
    Has Results
    • Relapsing-remitting Multiple Sclerosis
    • Rockland, Massachusetts
    • +1 more
    Jul 13, 2021

    Relapsing Multiple Sclerosis Trial in Worldwide (Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib)

    Recruiting
    • Relapsing Multiple Sclerosis
    • Beijin, China
      Peking University Third Hospital
    Jul 6, 2021

    Relapsing Multiple Sclerosis Trial in Worldwide (Remibrutinib, Teriflunomide)

    Recruiting
    • Relapsing Multiple Sclerosis
    • Hanford, California
    • +41 more
    Aug 5, 2022